Skip to main
GOSS
GOSS logo

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Gossamer Bio Inc. has garnered unusually bullish sentiment from key opinion leaders (KOLs), particularly regarding the expected success of its PAH treatment, PROSERA, with anticipated treatment effects ranging between 25m to 30m in the 6MWD metric. Despite some limitations in the phase 2 TORREY data, consistent benefits have been demonstrated across multiple endpoints, underscoring the product's potential with clean safety profiles and promising durability in long-term outcomes. The company has also seen increased investor interest following positive commentary at recent conferences, signaling strong market confidence in their pipeline and future growth potential.

Bears say

Gossamer Bio Inc. is facing a negative outlook primarily due to persistent mispricing in the market concerning the probability of success for its pipeline product, Seralutinib. Despite a recent increase in stock value, the underlying assumptions regarding Seralutinib's odds do not align with its clinical prospects, suggesting overvaluation. This disconnect raises concerns about the long-term viability of Gossamer Bio's financial foundation, particularly as it relates to its advancement in the competitive biopharmaceutical sector.

GOSS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Strong Buy based on their latest research and market trends.

According to 5 analysts, GOSS has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.